ASH 2022: Video interview with Veit L. Buecklein, MD on the outcomes of patients with diffuse large b-cell lymphoma treated in the United States compared to the European Union.
Home / Resource Library / What factors explain inferior survival for EU vs US patients with DLBCL after CAR T-cell therapy?